Compare BioNano Genomics Inc (BNGO) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Kraft Heinz Co — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Kraft Heinz Co trades at $24.55 (market cap $29.23B). The key difference: Kraft Heinz Co is far larger — about 2139.8× BioNano Genomics Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | KHC | |
|---|---|---|
Market Cap | $13.66M | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $28.06 |
52-Week Low | $1.06 | $21.21 |
Enterprise Value | $16.26M | $45.55B |
Dividend Yield | — | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Kraft Heinz (KHC) trades at $24.48, down 1.81% on the day, with a bearish technical signal and mixed sentiment. The stock shows attractive valuation ratios like a P/E of 13.04 and P/B of 0.81, but fundamentals are pressured by a net loss of $5.85 billion in 2025 and negative profit margins. Recent quarters have beaten EPS estimates, and the company maintains a $0.40 quarterly dividend, though dividend sustainability concerns persist amid earnings erosion.
The outlook is cautious; while the stock appears undervalued and dividend yield is high, ongoing profit declines and sector headwinds pose risks. Analyst consensus is mixed with a $24 price target, and institutional selling adds pressure. Key catalysts include the success of CEO Cahillane's turnaround strategy, but execution risks and competitive threats remain significant hurdles for shareholder value recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
